Cholinesterase inhibitor treatment in patients with delirium

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cholinesterase inhibitor treatment in patients with delirium. / Berg, Ronan M G; Möller, Kirsten.

In: The Lancet, Vol. 377, No. 9769, 12.03.2011, p. 900; author reply 901.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Berg, RMG & Möller, K 2011, 'Cholinesterase inhibitor treatment in patients with delirium', The Lancet, vol. 377, no. 9769, pp. 900; author reply 901. https://doi.org/10.1016/S0140-6736(11)60344-9

APA

Berg, R. M. G., & Möller, K. (2011). Cholinesterase inhibitor treatment in patients with delirium. The Lancet, 377(9769), 900; author reply 901. https://doi.org/10.1016/S0140-6736(11)60344-9

Vancouver

Berg RMG, Möller K. Cholinesterase inhibitor treatment in patients with delirium. The Lancet. 2011 Mar 12;377(9769):900; author reply 901. https://doi.org/10.1016/S0140-6736(11)60344-9

Author

Berg, Ronan M G ; Möller, Kirsten. / Cholinesterase inhibitor treatment in patients with delirium. In: The Lancet. 2011 ; Vol. 377, No. 9769. pp. 900; author reply 901.

Bibtex

@article{63a81b0fe3354841840ee8dfa5ce15b5,
title = "Cholinesterase inhibitor treatment in patients with delirium",
keywords = "Aged, Cholinesterase Inhibitors/adverse effects, Critical Illness, Delirium/complications, Humans, Intensive Care Units, Phenylcarbamates/adverse effects, Rivastigmine, Sepsis/complications",
author = "Berg, {Ronan M G} and Kirsten M{\"o}ller",
year = "2011",
month = mar,
day = "12",
doi = "10.1016/S0140-6736(11)60344-9",
language = "English",
volume = "377",
pages = "900; author reply 901",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9769",

}

RIS

TY - JOUR

T1 - Cholinesterase inhibitor treatment in patients with delirium

AU - Berg, Ronan M G

AU - Möller, Kirsten

PY - 2011/3/12

Y1 - 2011/3/12

KW - Aged

KW - Cholinesterase Inhibitors/adverse effects

KW - Critical Illness

KW - Delirium/complications

KW - Humans

KW - Intensive Care Units

KW - Phenylcarbamates/adverse effects

KW - Rivastigmine

KW - Sepsis/complications

U2 - 10.1016/S0140-6736(11)60344-9

DO - 10.1016/S0140-6736(11)60344-9

M3 - Journal article

C2 - 21397758

VL - 377

SP - 900; author reply 901

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9769

ER -

ID: 236994009